scholarly journals Design and Development of a Novel Drug Delivery Catheter for Atherosclerosis

2018 ◽  
Author(s):  
Sunandita Sarker ◽  
Yiannis S. Chatzizisis ◽  
Srivatsan Kidambi ◽  
Benjamin S. Terry
Keyword(s):  
Drug Delivery ◽  
High Risk ◽  
Arterial Wall ◽  
Local Treatment ◽  
Specific Treatment ◽  
Modern World ◽  
Design And Development ◽  
Anti Inflammatory ◽  
Delivery Catheter

Atherosclerosis is a chronic progressive cardiovascular disease that results from plaque formation in the arteries. It is one of the leading causes of death and loss of healthy life in modern world. Atherosclerosis lesions consist of sub-endothelial accumulations of cholesterol and inflammatory cells [1]. However, not all lesions progress to the final stage to cause catastrophic ischemic cardiovascular events [2]. Early identification and treatment of high-risk plaques before they rupture, and precipitate adverse events constitutes a major challenge in cardiology today. Numerous investigations have confirmed that atherosclerosis is an inflammatory disease [3] [4] [5]. This confirmation has opened the treatment of this disease to many novel anti-inflammatory therapeutics. The use of nanoparticle-nanomedicines has gained popularity over recent years. Initially approved as anticancer treatment therapeutics [6], nanomedicine also holds promise for anti-inflammatory treatment, personalized medicine, target-specific treatment, and imaging of atherosclerotic disease [7]. The primary aim of this collaborative work is to develop and validate a novel strategy for catheter-directed local treatment of high-risk plaque using anti-inflammatory nanoparticles. Preselected drugs with the highest anti-inflammatory efficacy will be incorporated into a novel liposome nanocarrier, and delivered in-vivo through a specially designed catheter to high-risk atherosclerotic plaques. The catheter has specially designed perfusion pores that inject drug into the blood stream in such a controlled manner that the streamlines carry the nanoparticles to the stenotic arterial wall. Once the particles make it to the arterial wall, they can be absorbed into the inflamed tissue. In this paper, we discuss the design and development of an atraumatic drug delivery catheter for the administration of lipid nanoparticles.

scholarly journals Development, Optimisation and Evaluation of Ketoprofen Lipospheres

2020 ◽  
Vol 11 (SPL4) ◽  
pp. 1853-1863
Author(s):  
Shubhra Rai ◽  
Gopal Rai ◽  
Ashish Budhrani
Keyword(s):  
Drug Delivery ◽  
Particle Size ◽  
Research Work ◽  
Extended Period ◽  
Entrapment Efficiency ◽  
Inflammatory Activity ◽  
Scanning Calorimetry ◽  
Anti Inflammatory

Lipospheres represent a novel type of fat-based encapsulation system produced for the topical drug delivery of bioactive compounds. The goal of this research work was to develop lipospheres, including ketoprofen applied for topical skin drug delivery. Ketoprofen lipospheres were formulated by melt emulsification method using stearic acid and Phospholipon® 90G. The lipospheres were analysed in terms of particle size and morphology, entrapment efficiency, Differential scanning calorimetry, In-vitro drug release, In-vivo (Anti-inflammatory activity). Outcomes of research revealed that particle size was found to be 9.66 µm and entrapment efficiency 86.21 ± 5.79 %. In-vivo, the study of ketoprofen loaded lipospheres formulation shows a higher plain formulation concentration in plasma (5.61 mg/mL). For dermis, ketoprofen retention was 27.02 ± 5.4 mg/mL for the lipospheres formulation, in contrast to that of the plain formulation group (10.05 ± 2.8 mg/mL). The anti-inflammatory effect of liposphere drug delivery systems was assessed by the xylene induced ear oedema technique and compared with marketed products. Finally, it seems that the liposphere drug delivery system possesses superior anti-inflammatory activity as compared to the marketed product gel consistencies. Liposphere may be capable of entrapping the medicament at very high levels and controlling its release over an extended period. Liposphere furnishes a proper size for topical delivery as well as is based on non-irritating and non-toxic lipids; it’s a better option for application on damaged or inflamed skin.

Adsorption of Alendronate onto Biomimetic Apatite Nanocrystals to Develop Drug Carrier Coating for Bone Implants

2012 ◽  
Vol 529-530 ◽  
pp. 475-479 ◽  
Author(s):  
Ruggero Bosco ◽  
Michele Iafisco ◽  
Jeroen van den Beucken ◽  
Sander C.G. Leeuwenburgh ◽  
John A. Jansen
Keyword(s):  
Drug Delivery ◽  
Surface Engineering ◽  
Drug Carrier ◽  
Local Treatment ◽  
Titanium Implants ◽  
Bone Implants ◽  
Bone Implant ◽  
Biomimetic Apatite

The possibility to develop a bone implant with bioactive aspects and in situ drug-delivery properties, in order to provide local treatment in vivo, is a big challenge. Where conventional surface modifications for bone implants focused on the deposition of ceramic (mostly calcium phosphate, CaP) coatings, current surface engineering approaches attempt to incorporate active features to render bone implant surfaces capable to direct biological performance. Biomimetic apatite nanocrystals (nAp) represent, among the CaPs, an elective material for bone applications and their surface functionalization with drugs allows them to act as a drug-delivery vehicle. Since load-bearing bone implants are increasingly used in patients with compromised health conditions, surface engineering is important to warrant the performance of these implants under such conditions. In view of this, bisphosphonates (BPs) represent a treatment modality for a variety of disorders of bone metabolism associated to bone loss, including Paget's bone disease, osteoporosis, fibrous dysplasia and bone metastases. In this work, we have synthesized and characterized bioinspired nAp and evaluated their functionalization with alendronate. In vitro tests will be used to evaluate the efficacy of the functionalized compound to impede the formation of osteoclasts and to show that alendronate-functionalized nAp can significantly reduce osteoclasteogenesis. Finally, alendronate-functionalized nAp (FnAp) has been deposited on titanium implants via the electrospray deposition technique in order to develop inorganic-organic coatings for bone implants with improved functionality.

Liposomal drug delivery of Corchorus olitorius leaf extract containing phytol using design of experiment (DoE): In-vitro anticancer and in-vivo anti-inflammatory studies

2021 ◽  
Vol 199 ◽  
pp. 111543
Author(s):  
Mohammad Hossain Shariare ◽  
Humaira Binte Noor ◽  
Junayet Hossain Khan ◽  
Jamal Uddin ◽  
Syed Rizwan Ahamad ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Design Of Experiment ◽  
Leaf Extract ◽  
Corchorus Olitorius ◽  
Liposomal Drug ◽  
Anti Inflammatory ◽  
Liposomal Drug Delivery

scholarly journals Formulation and Evaluation of Ibuprofen Loaded Lipospheres for Effective Oral Drug Delivery

2015 ◽  
Vol 14 (1) ◽  
pp. 17-27 ◽  
Author(s):  
MA Momoh ◽  
FC Kenechukwu ◽  
MS Gwarzo ◽  
PF Builders
Keyword(s):  
Drug Delivery ◽  
Encapsulation Efficiency ◽  
Oral Drug Delivery ◽  
Oral Drug ◽  
In Vitro Drug Release ◽  
Alternative Drug ◽  
Anti Inflammatory ◽  
Low Solubility

Ibuprofen (IBU) is an anti-inflammatory drug characterized by low solubility and bioavailabilty. This study was to develop IBU-liposphere and investigated for in vitro and in vivo performance. IBU free base was incorporated into lipospheres based on micronized beeswax and Phospholipon® 90H in the ratio of (1:3), via hot emulsification. IBU-loaded lipospheres were characterized based on morphology, encapsulation efficiency (EE%), and in vitro drug release. Analgesic, anti-inflammatory activities and the pharmacokinetics were similarly evaluated. Minimum and maximum encapsulation efficiency (EE%) of 89.4 and 97.9% were obtained for lipospheres A1 and A3, respectively. Stable, spherical and smooth lipospheres of size range 101 ± 0.30 to 178 ± 0.30 ?m were obtained. Minimum and maximum release of 75 and 96.9% were obtained for A1 and A3, respectively. Significant (p<0.005) analgesic and anti-inflammatory activities were achieved with prolong plasma concentration. IBU-lipospheres based on beeswax and phospholipid could be explored as an alternative drug delivery system.Dhaka Univ. J. Pharm. Sci. 14(1): 17-27, 2015 (June)

scholarly journals Development and Evaluation of Novel Self-Nanoemulsifying Drug Delivery Systems Based on a Homolipid from Capra hircus and Its Admixtures with Melon Oil for the Delivery of Indomethacin

2014 ◽  
Vol 2014 ◽  
pp. 1-9
Author(s):  
Nicholas C. Obitte ◽  
Kenneth C. Ofokansi ◽  
Franklin C. Kenechukwu
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Drug Delivery Systems ◽  
Tween 80 ◽  
Delivery Systems ◽  
Inflammatory Activity ◽  
Capra Hircus ◽  
Anti Inflammatory

In this study, goat fat (Capra hircus) and melon oil were extracted and used to formulate self-nanoemulsifying drug delivery systems (SNEDDS) based on either goat fat alone or its admixture with melon oil by employing escalating ratios of oil(s), surfactant blend (1 : 1 Tween 60 and Tween 80), and cosurfactant (Span 85), with or without carbosil, a glidant, for the delivery of indomethacin. The formulations were encapsulated in hard gelatin capsules and then assessed using isotropicity test, aqueous dilution stability and precipitation propensity, absolute drug content, emulsification time, in vitro drug release, and anti-inflammatory activity. The SNEDDS exhibited low precipitation propensity and excellent stability on copious dilution, as well as high drug release in vitro and in vivo. The inhibition produced by the SNEDDS was comparable to that of indomethacin injection (positive control) for much of the 5 h test period, indicating a high degree of bioavailability of the administered SNEDDS. The absolute drug contents and emulsification times fell within narrow limits. This study has shown that a 1 : 1 ratio of melon oil and goat fat could confer favourable properties with respect to drug release and anti-inflammatory activity on SNEDDS for the delivery of indomethacin, thus encouraging further development of the formulations.

scholarly journals The Anti-Inflammatory Activity of a Novel Fused-Cyclopentenone Phosphonate and Its Potential in the Local Treatment of Experimental Colitis

2015 ◽  
Vol 2015 ◽  
pp. 1-10
Author(s):  
Dorit Moradov ◽  
Helena Shifrin ◽  
Efrat Harel ◽  
Mirela Nadler-Milbauer ◽  
Marta Weinstock ◽  
...  
Keyword(s):  
Rat Model ◽  
Local Treatment ◽  
Experimental Colitis ◽  
Inflammatory Activity ◽  
Mucosal Inflammation ◽  
Activated Macrophages ◽  
Aminosalicylic Acid ◽  
Anti Inflammatory

A novel fused-cyclopentenone phosphonate compound, namely, diethyl 3-nonyl-5-oxo-3,5,6,6a-tetrahydro-1H-cyclopenta[c]furan-4-ylphosphonate (P-5), was prepared and testedin vitro(LPS-activated macrophages) for its cytotoxicity and anti-inflammatory activity andin vivo(DNBS induced rat model) for its potential to ameliorate induced colitis. Specifically, the competence of P-5 to reduce TNFα, IL-6, INFγ, MCP-1, IL-1α, MIP-1α, and RANTES in LPS-activated macrophages was measured. Experimental colitis was quantified in the rat model, macroscopically and by measuring the activity of tissue MPO and iNOS and levels of TNFαand IL-1β. It was found that P-5 decreased the levels of TNFαand the tested proinflammatory cytokines and chemokines in LPS-activated macrophages. In the colitis-induced rat model, P-5 was effective locally in reducing mucosal inflammation. This activity was equal to the activity of local treatment with 5-aminosalicylic acid. It is speculated that P-5 may be used for the local treatment of IBD (e.g., with the aid of colon-specific drug platforms). Its mode of action involves inhibition of the phosphorylation of MAPK ERK but not of p38 and had no effect on IκBα.

Sign in / Sign up

Export Citation Format

Share Document